Two-Drug HIV pill tested as potential new option
NCT ID NCT05630755
Summary
This study is testing if people with HIV who have their virus well-controlled on a standard three-drug pill can safely switch to a new two-drug pill (Doravirine/Islatravir). It will compare the new pill to staying on the current treatment to see if it works just as well at keeping the virus suppressed. The goal is to see if the new regimen is a safe and effective long-term option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AHF The Kinder Medical Group ( Site 1426)
Miami, Florida, 33133, United States
-
AccessHealth MA ( Site 1419)
Boston, Massachusetts, 02129, United States
-
Be Well Medical Center ( Site 1408)
Berkley, Michigan, 48072, United States
-
Center Hospital of the National Center for Global Health and Medicine ( Site 6601)
Shinjyuku-ku, Tokyo, 162-8655, Japan
-
Central Texas Clinical Research ( Site 1413)
Austin, Texas, 78705, United States
-
Clinica Universidad Catolica del Maule ( Site 2204)
Talca, Maule Region, 3465584, Chile
-
Clínica Universidad de Los Andes ( Site 2206)
Santiago, Region M. de Santiago, 7620001, Chile
-
DCOL Center for Clinical Research ( Site 1415)
Longview, Texas, 75605, United States
-
Guy's & St Thomas' NHS Foundation Trust ( Site 5808)
London, London, City of, SE1 9RT, United Kingdom
-
Hadassah Medical Center-Infecious Disease ( Site 4802)
Jerusalem, 9120, Israel
-
Holdsworth House Medical Practice ( Site 6200)
Darlinghurst, New South Wales, 2010, Australia
-
Holdsworth House Medical Practice - Brisbane ( Site 6201)
Brisbane, Queensland, 4006, Australia
-
Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 2205)
Temuco, Región de la Araucanía, 4781151, Chile
-
Infectious Disease Specialists of Atlanta ( Site 1403)
Decatur, Georgia, 30033, United States
-
KC CARE Health Center-Clinical Trials ( Site 1422)
Kansas City, Missouri, 64111, United States
-
Las Vegas Research Center ( Site 1436)
Las Vegas, Nevada, 89106, United States
-
Mercer University, Department of Internal Medicine ( Site 1411)
Macon, Georgia, 31201, United States
-
Midway Immunology and Research Center ( Site 1401)
Ft. Pierce, Florida, 34982, United States
-
Mills Clinical Research ( Site 1433)
Los Angeles, California, 90069, United States
-
National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 66
Osaka, 540-0006, Japan
-
National Hospital Organization Nagoya Medical Center ( Site 6603)
Nagoya, Aichi-ken, 460-0001, Japan
-
North Texas Infectious Diseases Consultants, P.A ( Site 1404)
Dallas, Texas, 75246, United States
-
Orlando Immunology Center ( Site 1407)
Orlando, Florida, 32803, United States
-
Pacific Oaks Medical Group ( Site 1400)
Beverly Hills, California, 90211, United States
-
Prahran Market Clinic ( Site 6202)
Melbourne, Victoria, 3181, Australia
-
Prism Health North Texas, Oak Cliff Health Center ( Site 1409)
Dallas, Texas, 75205, United States
-
Pueblo Family Physicians ( Site 1425)
Phoenix, Arizona, 85015, United States
-
Queen Elizabeth Hospital Birmingham ( Site 5809)
Birmingham, England, B15 2TH, United Kingdom
-
Rambam Health Care Campus-Institute of Allergy, Clinical Immunology, ( Site 4801)
Haifa, 3109601, Israel
-
Regional Center for Infectious Disease Research ( Site 1435)
Greensboro, North Carolina, 27401, United States
-
Royal Berkshire Hospital ( Site 5813)
Reading, RG1 5AN, United Kingdom
-
Royal Brisbane and Women's Hospital-Infectious Diseases Research ( Site 6204)
Brisbane, Queensland, 4029, Australia
-
Royal Free Hospital ( Site 5801)
London, England, NW32QG, United Kingdom
-
Royal Liverpool University Hospital ( Site 5812)
Liverpool, England, L7 8XP, United Kingdom
-
Royal London Hospital ( Site 5800)
London, England, E1 1BB, United Kingdom
-
Ruane Clinical Research Group, Inc ( Site 1414)
Los Angeles, California, 90036, United States
-
Sheba Medical Center-HIV unit ( Site 4803)
Ramat Gan, 5262100, Israel
-
Sourasky Medical Center ( Site 4804)
Tel Aviv, 64239, Israel
-
Southmead Hospital ( Site 5805)
Bristol, Bristol, City of, BS10 5NB, United Kingdom
-
St Hope Foundation ( Site 1410)
Bellaire, Texas, 77401, United States
-
St Vincent's Hospital-IBAC ( Site 6203)
Sydney, New South Wales, 2010, Australia
-
Texas Centers for Infectious Disease Associates ( Site 1406)
Fort Worth, Texas, 76104, United States
-
The Crofoot Research Center ( Site 1424)
Houston, Texas, 77098, United States
-
The Mortimer Market Centre for Sexual Health and HIV Research ( Site 5810)
London, London, City of, WC1E 6JB, United Kingdom
-
Therafirst Medical Center ( Site 1402)
Fort Lauderdale, Florida, 33308, United States
-
Triple O Research Institute, P.A ( Site 1417)
West Palm Beach, Florida, 33407, United States
-
Universidad de Chile - Hospital Clínico Universidad de Chile-Inmunologia Alergia y VIH ( Site 2200)
Santiago, Region M. de Santiago, 8380420, Chile
-
University Hospital of Wales ( Site 5803)
Cardiff, Wales, CF14 4XW, United Kingdom
-
Whitman-Walker Institute ( Site 1431)
Washington D.C., District of Columbia, 20005, United States
Conditions
Explore the condition pages connected to this study.